Pricing Log in Create free account
Friday 6 November 2026 Export HLN’s income statement to Excel — free account

Haleon PLC Sponsored ADR

HLN Healthcare Drug Manufacturers Specialty & Generic

Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.

9.13 0.10 −1.08%
Market cap
$40.2B
P/E
20.5×
Fwd P/E
16.5×
Dividend yield
2.16%
F-score
8/9
Altman Z
3.04
Beneish M
−2.60
Dividend safety
63/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 4.36%

Capital & Financial Ratios $m

Size
Market Cap 40,240.00
Revenue ttm 18,122.53
Net income ttm 3,070.88
Free cash flow ttm 4,551.19
Net debt Q 9,966.43
Valuation
P/E 20.48
Forward P/E 16.50
Price / sales 2.32
Forward P/S Powerpack
Price / FCF 9.23
Price / book 1.90
Financial health
Current ratio Q 0.69 (below 1: weak)
Debt / equity Q 0.50
Interest coverage Q 7.83
Growth
Revenue growth Q −0.32% (below 0%: shrinking)
Operating income growth Q —
EPS, this year +9.53%
EPS, next year A +6.57%
Revenue, next year A +3.82%
EPS, past 5 yrs +7.58%
EPS, next 5 yrs A +7.83%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.9×, against a ten-year median of 3.0×; over the ten years it ranged from 2.7× in 2024 to 3.5× in 2025.
P/B against its own 10 years 29.98%
10-year low 10-year high

Dividends raised every year since 2023

Yield
2.16%
Annual rate
0.20
Payout ratio
—
Growth, 2023–25
+33.4%/yr
  1. 0.10 ’23
  2. 0.16 ’24 +53
  3. 0.18 ’25 +17
  4. 0.11 ’26e −42
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,299 2,875 1,746 1,109
Receivables 2,422 2,745 2,800 3,151
Inventory 1,751 1,521 1,352 1,437
Other 521 166 103 62
5,993 7,307 6,000 5,759
2023 2024 2025 Q'26
Payables 4,386 4,735 4,919 5,095
ST’ Debt 816 1,900 1,102 2,633
Other 211 492 132 297
5,772 7,427 6,505 8,380

Compound Annual Growth %

10y 5y 3y
Sales — 1.43% 2.69%
Cash Flow — 12.50% 10.83%
Earnings — 6.98% 18.80%
Book Value — (9.48%) 2.21%

Earnings Trends EPS, adjusted, against the consensus

Sep 2024 Estimate 0.11 Actual 0.14

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2023 0.04 0.00 Miss by 0.04
Mar 2024 0.11 0.12 Beat by 0.01
Jun 2024 0.09 0.08 Miss by 0.01
Sep 2024 0.11 0.14 Beat by 0.03

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 0.49
’24 0.12 — 0.14 — 0.40
’23 0.10 0.09 0.10 — 0.28
’22 — — — — 0.28
’21 — — — — 0.41
’20 — — — — 0.34
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 14,545
’24 3,702 — 3,616 — 14,355
’23 3,627 7,263 3,542 — 14,059
’22 — — — — 13,430
’21 — — — — 12,899
’20 — — — — 13,551
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — — — — 3,473
’24 — — — — 2,940
’23 — — — — 2,612
’22 — — — — 2,552
’21 — — — — 1,834
’20 — — — — 1,927
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — 1,241 — — —
’25 — 1,199 — — 2,929
’24 — 1,339 — — 2,949
’23 — 771 — — 2,500
’22 — 757 — 2,176 2,191
’21 — — — — 1,834
’20 — — — — 1,927
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 11,158 13,551 12,899 13,430 14,059 14,355 14,545 18,123 +4.5% 15,101 15,679 16,293 +3.9%
Gross margin, % — — — 56.63 59.75 62.34 60.57 59.70 60.75 64.19 62.22 +7.6 pt
EBT — — — 1,166 2,179 2,211 2,001 2,025 2,441 2,838 3,405 +16.0%
EBT margin, % — — — 10.45 16.08 17.14 14.90 14.40 17.00 19.51 18.79 +9.1 pt
Net income — — — 862 1,568 0 1,384 1,382 1,885 2,215 3,071 +17.0%
Per share, $
Per share, $ Revenue — — — 2.41 2.93 2.79 2.91 3.05 3.14 3.24 0.00 +5.0%
Earnings — — — 0.19 0.34 0.41 0.28 0.28 0.40 0.49 0.45 +17.5%
Cash flow — — — 0.22 0.42 0.40 0.55 0.57 0.64 0.77 0.00 +23.1%
Capex — — — 0.00 0.00 0.00 (0.08) (0.02) 0.00 (0.12) 0.00 n/m
Free cash flow — — — 0.22 0.42 0.40 0.47 0.54 0.65 0.65 0.00 +19.6%
Book value — — — 7.78 7.74 7.71 4.41 4.51 4.54 4.84 0.00 (7.6%)
Shares, m — — — 4,621 4,621 4,621 4,618 4,617 4,566 4,491 — (0.5%)
Valuation, ×
Valuation, × P/E — — — 20.55 20.55 20.55 20.55 20.55 21.39 22.67 20.48 21.0
P/S — — — 0.00 0.00 0.00 0.00 0.00 2.42 2.57 2.32 0.7
P/B — — — 0.00 0.00 0.00 0.00 1.83 2.08 2.18 1.90 0.9
EV/Sales — — — 0.00 0.00 0.00 0.00 0.00 3.00 3.14 2.87 0.9
EV/FCF — — — 0.00 0.00 0.00 0.00 0.00 11.64 11.04 11.42 3.2
Cash, $m
Cash, $m Operating cash flow — — — 1,028 1,927 1,834 2,552 2,612 2,940 3,473 4,773 +22.5%
Capex — — — (320) (436) (403) (361) (112) 9 (545) (222) +9.3%
Free cash flow — — — 1,028 1,927 1,834 2,191 2,500 2,949 2,929 4,551 +19.1%
Balance, $m
Balance, $m Working capital — — — 2,029 1,362 1,369 (385) 221 (120) (505) (2,621) n/m
Net debt — — — 397 210 780 12,067 10,464 10,066 9,607 9,966 +70.0%
Shareholders’ equity — — — 35,949 35,770 35,615 20,356 20,809 20,733 21,737 22,064 (8.0%)
Returns, %
Returns, % ROA — — — 0.00 3.35 8.04 2.92 3.06 4.27 5.06 0.00 +5.1 pt
ROIC — — — 0.00 0.00 0.00 4.35 4.96 5.72 6.34 0.00 +6.3 pt
ROE — — — 0.00 4.37 5.26 4.69 6.34 8.87 10.35 0.00 +10.4 pt
People
People Employees — — — — — 22,800 24,622 25,408 24,561 24,535 — +1.9%
Revenue/emp, $m — — — 0.00 0.00 0.57 0.55 0.55 0.58 0.59 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026

Haleon PLC Sponsored ADR vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TAK Takeda Pharmaceutical Co. $67.7B 32.0× — +1.71% (above 0%: growing) −4.35% (below 0%: shrinking) +54.88% (above 0%: growing) 66.66% 16.51% Compare
TEVA Teva Pharmaceutical Industries Ltd. $48.7B 92.6× 30.7× −1.90% (below 0%: shrinking) −47.18% (below 0%: shrinking) −30.29% (below 0%: shrinking) 55.52% 16.25% Compare
HLN Haleon PLC Sponsored ADR $40.2B 20.5× 16.5× −0.32% (below 0%: shrinking) +40.00% (above 0%: growing) −42.94% (below 0%: shrinking) 62.88% 25.36%
ZTS Zoetis Inc. $33.9B 13.4× 14.2× −0.24% (below 0%: shrinking) +2.48% (above 0%: growing) +17.43% (above 0%: growing) 72.73% 37.56% Compare
UTHR United Therapeutics Corporation $24.3B 19.7× 22.5× +4.13% (above 0%: growing) −21.65% (below 0%: shrinking) −63.65% (below 0%: shrinking) 88.10% 36.97% Compare
VTRS Viatris Inc. $21.8B — (loss-making) 82.6× −0.28% (below 0%: shrinking) n/m +38.78% (above 0%: growing) 38.35% 6.97% Compare
NBIX Neurocrine Biosciences, Inc. $16.2B 23.0× 20.6× +41.24% (above 0%: growing) −3.67% (below 0%: shrinking) +79.00% (above 0%: growing) 97.63% 29.51% Compare
RDY Dr. Reddy's Laboratories Ltd $12.1B 44.4× 30.7× −10.09% (below 0%: shrinking) −36.84% (below 0%: shrinking) −70.49% (below 0%: shrinking) 52.13% 14.63% Compare
ELAN Elanco Animal Health Incorporated $11.8B — (loss-making) 161× +10.23% (above 0%: growing) +450.00% (above 0%: growing) +35.56% (above 0%: growing) 58.33% 7.97% Compare
Median of peers $23.0B 27.5× 30.7× +0.74% −4.35% +26.50% 62.50% 16.38%

All 84 Drug Manufacturers Specialty & Generic stocks →

Haleon PLC Sponsored ADR (HLN) Latest News

5 Nov

Impact 3 · · Simply Wall St.

4 Nov

Impact 3 · · Proactive Investors

30 Oct

Impact 3 · · Proactive Investors

29 Oct

Impact 4 · · TIKR
Impact 4 · · Moby
Impact 4 · · MarketBeat transcript
Impact 4 · · Investing.com
Impact 4 · · Proactive Investors

28 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

20 Oct

Impact 4 · · Proactive Investors

19 Oct

Impact 3 · · GlobeNewswire

18 Oct

Impact 3 · · Simply Wall St.

14 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

13 Oct

Impact 3 · · Simply Wall St.

28 Sep

Impact 4 · · Investing.com

25 Sep

Impact 4 · · Proactive Investors

24 Sep

Impact 4 ·

23 Sep

Impact 4 · · Proactive Investors

21 Sep

Impact 3 · · Insider Monkey

18 Sep

Impact 3 · · TheStreet

17 Sep

Impact 3 · · The Daily Upside

31 Jul

Impact 3 · transcript

30 Jul

Impact 4 · · MarketBeat transcript

29 Jul

Impact 3 ·

12 Jul

Impact 3 ·

9 Jul

Impact 3 ·

2 Jul

Impact 4 · · Barchart

HLN metrics, ten years each

stockrow.com/HLN · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com